Page 78 - Looking Statement News Today

Merck known as MSD outside the United States and Canada, today announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for KEYTRUDA for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [combined positive score ] as determined by a U.S. Food and Drug Administration -approved … Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...

Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced promising results from its latest pivotal trial for the Omnipod 5... | June 27, 2021

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting Font : A-A+ Data show ongoing durable responses beyond one year in monotherapy and in combination with Opdivo® in heavily pre-treated patients including one patient with prior progression on Opdivo® HOLON, Israel, June 8, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented ...

Share this article Share this article CUPERTINO, Calif., June 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 The first poster will discuss additional efficacy signals from a Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Previously reported data showed that DUR-928 was well tolerated at all three doses evaluated, 50mg QD, 150mg QD, and 300mg BID (600mg/day) with overall ...

TORONTO, ON / ACCESSWIRE / June 9, 2021 / AurCrest Gold Inc. (the "Company" or "AurCrest") (TSXV:AGO) is pleased to announce preliminary observations from the ongoing inaugural diamond drilling project

Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19 U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration Merck known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for m...

Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis Ongoing enrollment of a total of 16 patients in the UK, US and France Regulatory News: Lysogene (Paris:LYS) (FR0013233475 LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced dosing of the first patient, at Royal Manchester Childrens Hospital, part of Manchester University NHS Foundation Trust, in the global adaptati...

KEYNOTE-564 is the First Phase 3 Study to Show Positive Results for Adjuvant Immunotherapy in RCC First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting Merck known as MSD outside the United States and Canada, today announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the potential adjuvant … KEYNOTE-564 is the First Phase 3 Study to Show Positive Results for Adjuvan...

Organon (NYSE: OGN), today celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange (NYSE).

TechnipFMC (NYSE:FTI) (PARIS:FTI) (ISIN:GB00BDSFG982) today has been awarded its first integrated Engineering, Procurement, Construction and Installation (iEPCI) contract in Brazil by Karoon Energy (ASX:KAR)